Patients with the kidney disease, C3 glomerulopathy, who were taking 200 mg of iptacopan — also called Fabhalta — twice daily for six months were found to directly reduce the amount of protein in their urine when combined with background therapies. The drug’s safety profile was also consistent, according to the Dec. 11 news release.
“People living with C3 glomerulopathy have no approved treatment options indicated for this progressive disease, posing many challenges and uncertainty for these mostly young patients,” Shreeram Aradhye, MD, the president of development and chief medical officer at Novartis stated. “These positive results demonstrate the potential of iptacopan to provide clinically meaningful benefit in C3G and add to our growing body of evidence that supports its use across multiple complement-mediated diseases.”
The company also just received FDA approval Dec. 5 for the drug, which was shown in separate trials to make improvement in the absence of transfusions as the first oral monotherapy for adults with a rare blood disease.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
